Lp(a) anticorps

N° du produit ABIN969261

Cité dans 2 publications. Cet anticorps anti-Lp(a) Monoclonal Souris (Clone 8F6A9) (ABIN969261) détecte spécifiquement Lp(a) dans ELISA et IHC. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour Lp(a) anticorps (ABIN969261)

Antigène: Lp(a) (Lipoprotein (Lp(a)))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Lp(a) est non-conjugé

Application: ELISA, Immunohistochemistry (IHC)

Clone: 8F6A9

Détail du produit anti-Lp(a) anticorps

Fonction: LPA Antibody

Purification: Ascitic fluid

Immunogène: Purified recombinant fragment of LPA (1823-2013) expressed in E. Coli.

Isotype: IgG1

Information d'application

Indications d'application: ELISA: 1/10000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Références pour anticorps anti-Lp(a) (ABIN969261)

Ranga, Kalra, Tandon, Gambhir, Mehrotra: "Effect of aspirin on lipoprotein(a) in patients with ischemic stroke." dans: Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, Vol. 16, Issue 5, pp. 220-4, (2007) (PubMed).

Catalano, Cortelazzo, Yilmaz, Perilli, Carzaniga, Emanuele: "The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease." dans: Clinica chimica acta; international journal of clinical chemistry, Vol. 387, Issue 1-2, pp. 109-12, (2007) (PubMed).

Détails sur Lp(a)

Antigène: Lp(a) (Lipoprotein (Lp(a)))

Autre désignation: LPA

Sujet: LPA: lipoprotein, Lp(a). Apo(a) is the main constituent of lipoprotein(a) (lp(a)). It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1.Lp(a) may be a ligand for megalin/gp 330.Apo(a) is known to be proteolytically cleaved, leading to the formation of the so-called mini-lp(a).Apo(a) fragments accumulate in atherosclerotic lesions,where they may promote thrombogenesis.O-glycosylation may limit the extent of proteolytic fragmentation.

UniProt: P08519